Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.14B P/E 22.67 EPS this Y -23.80% Ern Qtrly Grth 105.30%
Income 96.34M Forward P/E 15.43 EPS next Y 19.40% 50D Avg Chg -7.00%
Sales 118.31M PEG 0.92 EPS past 5Y 12.40% 200D Avg Chg -6.00%
Dividend N/A Price/Book 1.76 EPS next 5Y 20.00% 52W High Chg -23.00%
Recommedations 2.00 Quick Ratio 19.17 Shares Outstanding 17.96M 52W Low Chg 39.00%
Insider Own 2.35% ROA -0.10% Shares Float 17.57M Beta 0.92
Inst Own 95.61% ROE 13.26% Shares Shorted/Prior 795.62K/672.08K Price 66.21
Gross Margin 71.67% Profit Margin 81.43% Avg. Volume 97,087 Target Price 116.80
Oper. Margin 9.65% Earnings Date Aug 6 Volume 54,918 Change -0.73%
About Ligand Pharmaceuticals Incorpor

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

LGND Chatroom

User Image kellyCriterion101 Posted - 1 day ago

$VKTX Pretty good read https://www.nature.com/articles/s41591-024-02996-7 very repeatable in GLP-GIP type drugs. In late December I was present when they showed partially mature SELECT data on CV benefit and it seemed to not benefit (on a statistically significant basis) those who are super obese. But this mature data set says otherwise. Of course, this is all baked well into VKTX, but one thing is for certain, GLP-GIP drugs will only get bigger and get more coverage from payers and state. The value of making sure the obese person in your family lives long enough to see their lineage's kids is immeasurable. A reduction in CV events is not something you can ignore. I continue to think the synergy of VK5211 and VK2735 are a complete package for a buyer to negotiate with VKTX and $LGND to own the asset. My ass is burnt this week for sure along with other longs, my average is 63, while the other LT guys here are in from <30. I would buy up here but my exposure is huge. Drawdown sucks, but I know what I hold. Do you?

User Image Capitulation_0 Posted - 2 days ago

$AGEN 100m financing by $LGND Big hedge funds. $30 pre-R/S. FDA type B. Everything is lining up.

User Image Kazusflute Posted - 6 days ago

@TimingTimingTiming @JayDSpra and $AGEN has been a bad stock — not yet settled from RS. Haven’t followed it closely, and only recently invested. Cursory research shows $LGND to be a highly discerning investor/partner … 200mm of support indicates a promising upside for the stock… still in the range of all-time lows…

User Image StockInvest_us Posted - 1 week ago

Signal alert: $LGND - Double Bottom https://stockinvest.us/l/Ip0ylwZYBM

User Image DameWave Posted - 1 week ago

$FBIO One year graph with FBIO in blue vs peers I've written about here before (see previous posts about comparison in sales and market cap). Writing it again, never seen such a mispriced/cheap stock. 8 commercial and 25 clinical products, which together are valued at less than $1 M each, when sales were $84.5 M in 2023 and there are completed deals worth about $900 M. It is extremely difficult today, for me, to see how DFD-29, Cosibelimab, Dotinurad and CUTX -101, all of which have presented their efficacy and safety from Phase 3 (Dotinated Japan, see previous post), should fail not to sell for over $1 B each in total sales (some for significantly more). FBIO market cap today? $32 M. $XOMA $LGND $RPRX

User Image DameWave Posted - 1 week ago

$FBIO $XOMA Reports Q1 revenue $1.5M and the stock is trading up 5% ($296 M market cap)... $LGND +17% last week... When will the market find and understand $FBIO? $XBI $IBB

User Image Doozio Posted - 1 week ago

chop chop huckleberries 🧠⏰♾️ gonna be $lgnd ary!

User Image StockInvest_us Posted - 1 week ago

Signal alert: $LGND - Double Bottom https://stockinvest.us/l/L3xroYgcyv

User Image DameWave Posted - 1 week ago

$FBIO Ligand $LGND flying on Q1 report. While $FBIO ownership shares in 9 companies, future royalties and annual dividends trade at a value of? -$5 M (yes, minus) ... How is that possible? Because $FBIO 53% ownership in $DERM is valued at over $39 M and the entire $FBIO is valued at $34 M... $XBI https://investor.ligand.com/news-and-events/press-releases/news-details/2024/Ligand-Reports-First-Quarter-2024-Financial-Results/default.aspx

User Image fda_tracker Posted - 1 week ago

$LGND New PDUFA Date 2024-09-05 LIGAND PHARMACEUTICALS INCORPORATED Link:http://www.businesswire.com/news/home/20240507633610/en/Ligand-Reports-First-Quarter-2024-Financial-Results Calendar:http://www.fdatracker.com/fda-calendar/

User Image Scooter0732 Posted - 1 week ago

$AGEN Viking Therapeutics is another company Ligand did a deal with a few years back… and we all know how that story played out. Now it’s Agenus’s turn, which shows that Ligand has an eye for picking biotech with VERTICAL potential. $VKTX $LGND

User Image epsguid Posted - 1 week ago

$LGND reported earnings of $3.84, consensus was $0.82 via @eWhispers #epsbeat http://eps.sh/d/lgnd

User Image ace6th Posted - 1 week ago

$AGEN Dancing with the big boys now $AGEN + $LGND

User Image Stock_Titan Posted - 1 week ago

$LGND $AGEN Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement https://www.stocktitan.net/news/LGND/ligand-and-agenus-enter-into-100-million-royalty-financing-hthgktn83jf9.html

User Image TalkMarkets Posted - 1 week ago

Don't Overlook These Top Medical Stocks As Q1 Earnings Approach $LGND $PEN $OSCR https://talkmarkets.com/content/stocks--equities/dont-overlook-these-top-medical-stocks-as-q1-earnings-approach?post=444365

User Image DameWave Posted - 2 weeks ago

$FBIO Why is Fortress Biotech significantly undervalued? (Part 200 or something) $XBI $XOMA is another royalty peer that is probably most similar to Fortress as they invest in an earlier event. Total Revenues 2023 Ligand Pharmaceuticals $LGND: $131,3 M Fortres Biotech: $84,5 M Xoma: $4,8 M Market Cap Today: Ligand Pharmaceuticals: $1328 M Xoma: $289 M Fortres Biotech: $33 M And then Fortress is also a co-owner in all of its 11 companies (majority owner in several, see previous posts).

User Image DameWave Posted - 2 weeks ago

$FBIO Another peer to Fortress Biotech, $RPRX and DRI Healthcare Trust is, as I understand it, Ligand Pharmaceuticals $LGND (haven't had time to check them): https://investor.ligand.com/files/doc_financials/2023/q4/02/Q4-2024-Earnings-Release-Slides_Final-v2-2-27-24.pdf $XBI

User Image StockInvest_us Posted - 04/24/24

Signal alert: $LGND - Oversold Trend Short (Undervalued) https://stockinvest.us/l/qWXH9IF0I1

User Image Stock_Titan Posted - 04/23/24

$LGND Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 https://www.stocktitan.net/news/LGND/ligand-to-report-first-quarter-2024-financial-results-on-may-7-yjicfzsg4j3x.html

User Image novumcarpediem Posted - 1 month ago

@LeLionEtLeRat It's crazy. How can these companies be so naive and trust disclosing their IP to Wuxi ?! These companies $LGND and $KYTX are done. I wouldn't even be surprised if these Cos lose their FTO from patent and Tech theft.

User Image LeLionEtLeRat Posted - 1 month ago

@novumcarpediem thanks for the note! $LGND is not mention but they're exposed too. https://investor.ligand.com/news-and-events/press-releases/news-details/2018/Ligand-Receives-47-Million-from-WuXi-Biologics-for-Expansion-of-Worldwide-OmniAb-Platform-License-Agreement-06-27-2018/default.aspx

User Image vjtweet Posted - 1 month ago

$LGND opened long

User Image Okenrav Posted - 1 month ago

@LeLionEtLeRat Thanks! The Chinese are losing this one. $VKTX got all the drugs they're developing right now from $LGND . So there is a paper trail of the development of these molecules. I do not see this as something that would impede a BO.

User Image Unicorn2020 Posted - 1 month ago

$TSVT Back in @ $5.00 this morning. we will trade in tandem with $LGND

User Image Stock_Titan Posted - 1 month ago

$LGND Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference https://www.stocktitan.net/news/LGND/ligand-pharmaceuticals-announces-new-topiramate-injection-data-e88o8stfth4g.html

User Image StockInvest_us Posted - 1 month ago

Signal alert: $LGND - PivotPoint bottom https://stockinvest.us/l/3X4ldloAco

User Image Stock_Titan Posted - 1 month ago

$LGND Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ https://www.stocktitan.net/news/LGND/ligand-pharmaceuticals-announces-launch-of-pelthos-therapeutics-to-zmpyde9ki690.html

User Image hooks2 Posted - 03/28/24

$LGND

User Image hooks2 Posted - 03/28/24

$LGND

User Image hooks2 Posted - 03/28/24

$LGND

Analyst Ratings
HC Wainwright & Co. Buy May 8, 24
Benchmark Buy Apr 12, 24
HC Wainwright & Co. Buy Feb 29, 24
Benchmark Buy Dec 13, 23
HC Wainwright & Co. Buy Sep 19, 23
Benchmark Buy Aug 23, 23
HC Wainwright & Co. Buy Aug 9, 23
Barclays Overweight Jul 25, 23
HC Wainwright & Co. Buy Jun 2, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Davis Todd C CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Sep 22 Buy 59.3822 4,000 237,529 73,090 09/25/23
KOZARICH JOHN W Director Director May 16 Sell 77.2009 4,444 343,081 38,488 05/18/23
KOZARICH JOHN W Director Director May 08 Sell 76.8 6,408 492,134 42,213 05/10/23
KOZARICH JOHN W Director Director May 08 Option 18.82 6,408 120,599 48,621 05/10/23
Reardon Andrew See Remarks See Remarks Mar 24 Sell 69.9243 300 20,977 16,308 03/28/23
HIGGINS JOHN L Director Director Dec 16 Sell 61.8657 10,000 618,657 422,984 12/20/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Sep 16 Sell 88.06 1,000 88,060 366,180 09/22/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Sep 15 Sell 89.68 5,000 448,400 364,180 09/16/22
FOEHR MATTHEW W President and COO President and COO May 13 Buy 82.7638 2,500 206,910 173,354 05/13/22
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer May 09 Option 21.92 8,000 175,360 348,593 05/10/22
KOZARICH JOHN W Director Director May 13 Option 10.12 4,835 48,930 34,543 05/13/21
Davis Todd C Director Director Feb 12 Option 195.91 2,474 484,681 50,152 02/12/21
Davis Todd C Director Director Feb 12 Sell 213.14 5,083 1,083,391 47,678 02/12/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Feb 09 Option 12.26 114,666 1,405,805 346,030 02/09/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Feb 09 Sell 203.4 54,666 11,119,064 286,030 02/09/21
Berkman Charles S SVP, Gen. Counsel &.. SVP, Gen. Counsel & Secretary Feb 05 Sell 178.5 18,097 3,230,314 28,906 02/05/21
FOEHR MATTHEW W President and COO President and COO Feb 05 Option 48.17 45,547 2,193,999 212,745 02/05/21
FOEHR MATTHEW W President and COO President and COO Feb 05 Sell 176.86 44,547 7,878,582 168,198 02/05/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Jan 27 Option 16.95 120,000 2,034,000 273,422 01/27/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Jan 27 Sell 170.5 90,000 15,345,000 243,422 01/27/21
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Dec 09 Option 10.05 14,657 147,303 236,770 12/09/20
HIGGINS JOHN L Chief Executive Offi.. Chief Executive Officer Nov 10 Option 10.05 20,000 201,000 224,571 11/10/20